He spent thirty years turning lab science into products doctors actually use. Now he is betting that a synthetic peptide can beat the antibody at its own game.
The antibody is the most valuable molecule in modern medicine. It finds one target among billions and locks on with almost unreasonable precision. It also costs a fortune to make, needs to be grown in living cells, and travels the world inside a cold chain that cannot break. For forty years the industry has accepted that trade: pay the price, because nothing else binds like it. Albert A. Luderer built a company on a stubborn refusal to accept it.
Luderer is the co-founder and chief executive of Indi Molecular, a biotech in Culver City, California, working on a class of molecules with a mouthful of a name - protein catalyzed capture agents, or PCCs. The short version: synthetic peptides, built in a chemistry lab, engineered to bind a target as tightly as an antibody would. If they work at scale, they promise antibody-grade precision without antibody-grade cost and fragility. That is the bet. Luderer has spent his whole career getting ready to make it.
Before Indi Molecular, there was a career that reads like a tour of how diagnostics actually got built. Luderer earned his Ph.D. at Rutgers University as a National Science Foundation pre-doctoral fellow, then did postgraduate work in immunology at Jefferson Medical College. From there he moved into industry and mostly stayed on the hardest part of it - the stretch where a promising piece of science has to become a product a clinical lab will trust every single day.
He held senior roles at Corning, Ciba Corning, Boehringer Mannheim (now part of Roche), and Dianon Systems (now part of LabCorp). He co-invented Vitek II, a system for microbial detection and antibiotic susceptibility testing that became a global market leader in clinical microbiology. He helped establish standard-of-care diagnostics in cancer detection, and he was part of the joint venture work that helped create what became Siemens Diagnostics. This is not the flashy end of biotech. It is the plumbing. And Luderer clearly likes the plumbing.
He ran companies, too. He was president and chief operating officer of bioMerieux. He was chief executive of the venture-backed therapeutics company Light Sciences. And he was president, CEO and director of BioTrove, a molecular tools company that Life Technologies acquired in 2009 - the same year BioTrove won a Frost & Sullivan leadership award and landed on the Inc. 5000 list of the fastest-growing companies in North America. Somewhere across those roles, a pattern sets in: take deep science, find the part that matters commercially, and carry it all the way to a shipping product.
Indi Molecular was spun out of Integrated Diagnostics in 2013. The science came from the Caltech lab of James Heath, a chemist known for advancing in situ click chemistry screening. The third name on the founding document belongs to Leroy Hood, one of the pioneers of systems biology. Between them, Heath and Hood are about as heavyweight as scientific founders get. What they needed was someone who had spent decades doing the unglamorous translation work - the part where a lab result becomes a company. That was Luderer, and he took the CEO seat.
There is a version of the founding CEO job that gets very little attention. Not the visionary on stage, but the person who decides which experiments become milestones, which milestones become a roadmap, and which roadmap a partner or investor will actually fund. Luderer had done that repeatedly before Indi. Choosing him was less a gamble than a recognition of what the company needed: someone who could stand between a Caltech bench and a clinical reality and keep the two talking.
Here is the idea in plain terms. Antibodies are proteins your immune system makes to grab onto specific targets. They are brilliant at it. But because they are large biological molecules, they are expensive to produce, sensitive to heat, and slow to develop. PCCs try to reproduce the grabbing without the biology. They are synthetic peptides - short chains of amino acids - assembled and screened using click chemistry, a fast way of snapping molecular pieces together. The screen searches enormous peptide libraries for the rare combination that binds a chosen target with high affinity.
The company can tune these molecules using tricks unavailable to biology - unnatural D-amino acids for stability, cyclic structures, cooperative binding where two arms of a molecule grip the same target. The aim is binders that reach nano-molar and even pico-molar affinity, the range where antibodies live. And because they are chemistry, the same specs that make or break any small-molecule drug come back into play: water solubility, renal clearance, in vivo activity. Getting a molecule that binds is one thing. Getting one that binds, dissolves, travels, and clears cleanly is the real work.
Indi Molecular has pointed its platform at oncology - specifically at synthetic small-molecule targeted therapeutics. Among the targets is KRAS G12D, a mutation that drives some of the most aggressive pancreatic cancers and has spent years wearing the label "undruggable." The company has also worked on ovarian cancer and folate-receptor targeting. Alongside the therapeutic program, the same capture-agent chemistry lends itself to imaging: attach the right tag and a PCC becomes a PET tracer that lights up where a target lives in the body.
That imaging angle led to a collaboration with GE Healthcare to develop PET tracer candidates, and in 2017 the company closed a Series A financing of roughly $11.5 million. It is a reminder that Indi Molecular sits precisely at the seam of Luderer's two careers - diagnostics and therapeutics - which is probably no accident. A molecule that can find a tumor is a diagnostic. The same molecule, weaponized, is a drug. He has spent decades on both sides of that line.
If there is a through-line to Luderer's career, it is patience with the unglamorous middle. The headlines in biotech go to the discovery and the exit. The years in between - the assay validation, the manufacturing scale-up, the regulatory grind, the partner negotiations - are where most companies quietly die. Luderer keeps choosing that middle. Vitek II was a middle. BioTrove was a middle that ended in an acquisition. Indi Molecular is a middle he is still walking.
He has also stayed close to the broader field as a board member and advisor, including work with Bionano Genomics and PrimeraDx. It fits the profile of someone whose value is not a single idea but a way of thinking - a sense, earned over decades, for whether a piece of science can survive contact with a real clinic. That instinct is hard to fund and harder to fake. It is the reason two of the biggest names in life sciences handed him the keys to their spinout.
Whether PCCs ultimately dethrone the antibody is an open question, and an honest one. Plenty of elegant platforms have run aground on the specifics of human biology. But the ambition is clear, and it is characteristic: take something biology does beautifully and expensively, and ask whether chemistry can do it cheaply and at will. It is a question worth a career. Luderer has given it one.